Fatty Acid Supplementation in Children With ASD
Completed · Phase 2 · Has a placebo group
Conditions studied: Autism Spectrum Disorder
In brief
The purpose of this study is to examine how fatty acid supplementation alters biological signatures in children with ASD
Key facts
- Study ID
- NCT03550209
- Run by
- Sarah Keim
- People needed
- 72
- Starts
- 2018-06-28
- Expected to finish
- 2020-01-10
- Last updated by the study team
- 2021-08-03
Who can join
Age: 2 and older, up to 6. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 2-6 years old
- ASD diagnosis at Nationwide Children's Hospital within the prior 6 months
- ADOS-2 score in "autism" (severe) range
- English is primary language
You may not qualify if…
- Fatty acid supplementation in the past 6 months
- Consumes fatty fish more than 3 times per week
- Still breastfeeding or formula feeding
- Quadriparesis
- Deafness
- Blindness
- Seizure disorder diagnosis
- Autoimmune disorder including Type 1 Diabetes, Fragile X, Rett, Angleman Syndromes, Tuberous Schlerosis
- Feeding problems precluding consumption of the supplement
- Ingredient allergy (canola, fish, or borage seed)
- Planned surgeries scheduled within the time frame of trial participation
Where it is running
- Nationwide Children's Hospital — Columbus, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.